A hypoglycemic agent
Related Products
Labeled Version(s)
30151Nateglinide-d5
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Nateglinide

Item No. 23320

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-D-phenylalanine
CAS Number
105816-04-4
Synonyms
  • A-4166
  • SDZ-DJN 608
Molecular Formula
C19H27NO3
Formula Weight
317.4
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlEthanol: 30 mg/ml
λmax
207 nm
SMILES
CC(C)[C@@H]1CC[C@@H](C(N[C@@H](C(O)=O)CC2=CC=CC=C2)=O)CC1
InChi Code
InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15-,16-,17-/m1/s1
InChi Key
OELFLUMRDSZNSF-BRWVUGGUSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    250 mg

    $49

    Add

    500 mg

    $82

    Add

    1 g

    $143

    Add

    5 g

    $423

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Nateglinide is a hypoglycemic agent.1,2,3 It induces insulin and somatostatin release from perfused rat pancreas when used at concentrations ranging from 0.03 to 3 μM.1 Nateglinide (3 µM) increases intracellular calcium levels in isolated rat pancreatic β cells, an effect that can be inhibited by the L-type calcium channel blocker nitrendipine (Item No. 17549). Nateglinide-induced secretion of insulin and somatostatin and calcium influx is also reversed by the potassium channel activator diazoxide (Item No. 14576). Oral administration of nateglinide (1.6 mg/kg) reduces blood glucose levels by 20% in fasted mice.2 It also decreases blood glucose levels in an oral glucose tolerance test in normal rats, genetically diabetic KK mice, and a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104).3 Formulations containing nateglinide have been used in the treatment of type 2 diabetes.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Fujitani, S., Ikenoue, T., Akiyoshi, M., et al. Somatostatin and insulin secretion due to common mechanisms by a new hypoglycemic agent, A-4166, in perfused rat pancreas. Metabolism 45(2), 184-189 (1996).

    2. Shinkai, H., Toi, K., Kumashiro, I., et al. N-acylphenylalanines and related compounds. A new class of oral hypoglycemic agents. J. Med. Chem. 31(11), 2092-2097 (1988).

    3. Sato, Y., Nishikawa, M., Shinkai, H., et al. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res. Clin. Pract. 12(1), 53-59 (1991).